Ecklonia cava Extract for Induced Pluripotent Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing induced pluripotent stem cells from mesenchymal stem cells face challenges in safety, efficiency, and ethical concerns, with existing techniques posing risks of cancer and low efficiency, particularly when using viral vectors or requiring large numbers of eggs.
Innovation Solution
A medium composition containing Ecklonia cava extract is used to dedifferentiate mesenchymal stem cells into induced pluripotent stem cells, which can then be efficiently differentiated into neurons, offering a safe and efficient method for cell therapy products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fusion with ES cells is used to produce induced pluripotent stem cells, then pluripotent stem cells can be obtained, but the cells have two pairs of genes which causes instability
Solution Approach 1:
The patent extracts and eliminates the problematic viral vector integration step from the reprogramming process. Instead of using viral vectors that integrate into the genome (causing dual gene pairs and instability), the invention uses a cell-free extract system that delivers reprogramming factors without genomic integration, thereby obtaining stable induced pluripotent stem cells without genetic complexity
Solution Approach 2:
The patent introduces a cell-free extract as an intermediary medium that transfers reprogramming information without direct viral integration. The extract from 293T cells serves as a mediator that delivers functional reprogramming factors while avoiding the harmful effect of viral genome integration, thus resolving the stability issue
2Productivity
If somatic cell nuclear transfer is used to produce induced pluripotent stem cells, then pluripotent stem cells can be obtained, but it requires a large number of eggs and has very low efficiency
Solution Approach 1:
The patent replaces the complex mechanical and biological procedure of somatic cell nuclear transfer (which requires egg cells and has low efficiency) with a simple cell-free extract system. This substitution eliminates the need for egg cells and achieves high efficiency in producing induced pluripotent stem cells through a streamlined protocol
3Reliability
If reprogramming by gene factor using viruses containing oncogenes is used, then induced pluripotent stem cells can be produced, but it poses a high risk of cancer occurrence and has low efficiency
Solution Approach 1:
The patent extracts and removes the harmful oncogenic viral components from the reprogramming process. By using a cell-free extract system instead of viral vectors containing oncogenes, the invention eliminates cancer risk while maintaining reprogramming efficiency, thus producing safe induced pluripotent stem cells
Solution Approach 2:
The patent converts the harmful effect of viral integration and oncogene expression into a beneficial cell-free system. By utilizing cell-free extracts that contain reprogramming factors without the harmful viral genome, the invention transforms a potentially dangerous approach into a safe and efficient method for generating induced pluripotent stem cells
Data Source
Figure 1~2
Figure 3~4
Figure 5a~6D
AI summary
The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiating an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell, produced by using the medium composition into a neuron. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into neurons.